Table 2.

Baseline characteristics of 291 patients with one mutation by the type of therapy

Matched (%)Nonmatched (%)
Covariate(n = 175)(n = 116)P
Age, y<6096 (55)61 (53)0.80
≥6079 (45)55 (47)
SexMale86 (49)47 (41)0.19
Female89 (51)69 (59)
Number of prior therapies≤355 (31)33 (28)0.68
>3120 (69)83 (72)
Performance status052 (30)38 (33)0.77
1113 (65)73 (63)
2+10 (6)5 (4)
Platelet count, × 109/L<14025 (14)20 (17)0.78
≥140–<440143 (82)92 (79)
≥4407 (4)4 (3)
Number of metastatic sites≤2101 (58)71 (61)0.64
>274 (42)45 (39)
Liver metastasesYes97 (55)74 (64)0.20
No78 (45)42 (36)
Lactate dehydrogenase ≥ 618 IU/LYes50 (29)47 (41)0.05
No125 (71)69 (59)
Albumin < 3.5 g/dLYes17 (10)8 (7)0.53
No158 (90)108 (93)
Royal Marsden Hospital score0 or 1133 (76)92 (79)0.61
2 or 342 (24)24 (21)